DMK Pharmaceuticals Corporation
CY3B
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 9.10K | 6.90K | 1.45M | 2.15M | 1.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.10K | 6.90K | 1.45M | 2.15M | 1.51M |
| Cost of Revenue | 338.50K | 361.40K | 1.79M | 2.48M | 1.65M |
| Gross Profit | -329.40K | -354.40K | -335.10K | -331.10K | -141.90K |
| SG&A Expenses | 2.40M | 2.63M | 4.78M | 3.15M | 2.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.16M | 3.37M | 7.88M | 6.49M | 6.13M |
| Operating Income | -3.15M | -3.36M | -6.43M | -4.34M | -4.63M |
| Income Before Tax | -1.74M | -7.00M | -9.01M | -3.40M | -4.27M |
| Income Tax Expenses | -- | -- | -- | 2.00K | -- |
| Earnings from Continuing Operations | -1.74M | -7.00M | -9.01M | -3.40M | -4.27M |
| Earnings from Discontinued Operations | 348.20K | -1.57M | 71.70K | 75.50K | -127.70K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.39M | -8.57M | -8.94M | -3.33M | -4.40M |
| EBIT | -3.15M | -3.36M | -6.43M | -4.34M | -4.63M |
| EBITDA | -3.08M | -3.28M | -6.32M | -3.97M | -4.23M |
| EPS Basic | -0.20 | -3.40 | -4.09 | -1.55 | -2.05 |
| Normalized Basic EPS | -0.14 | 0.23 | -2.58 | -1.14 | -1.25 |
| EPS Diluted | -0.20 | -3.40 | -4.17 | -1.55 | -2.05 |
| Normalized Diluted EPS | -0.14 | 0.23 | -2.58 | -1.14 | -1.25 |
| Average Basic Shares Outstanding | 7.07M | 2.57M | 2.18M | 2.14M | 2.14M |
| Average Diluted Shares Outstanding | 7.07M | 2.57M | 2.18M | 2.14M | 2.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |